צמיחה צפויה ברווח למניה לשנה הבאה BioSig Technologies (BSGM)

Biosig Technologies (BSGM) is developing the PureEP ecosystem, although management complexities have slowed the order inflow. Revenues are based on software licensing and ECG consumables. Noise-reduction technologies allow the company to compete against medtech behemoths. The trajectory of forward EPS estimates reflects current dynamics, where the indicator level stands at 32.60, helping to assess capital freeze risks.

The commercial success of PUREEP systems in cardiology directly determines the future profitability of Biosig Technologies (BSGM), transforming equipment sales into expected net income. This indicator measures the consensus forecast for earnings per share growth, reflecting market confidence in business scaling, while overly optimistic 12-month EPS growth targets from analysts may signal that the asset is overbought.